Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Expanded Access Protocol for ZMapp (Anti-Ebola monoclonal antibody)

Next Previous
X
Search
Trial Profile

An Expanded Access Protocol for ZMapp (Anti-Ebola monoclonal antibody)

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 27 Oct 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Porgaviximab (Primary)
  • Indications Ebola virus infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 27 Oct 2016 New trial record
    • 12 Oct 2016 According to a Mapp Biopharmaceutical media release, the U.S. Food and Drug Administration (FDA) has approved an Expanded Access Protocol (EAP) for ZMapp. The company will also make appropriate regulatory submissions in the three West African countries that participated in PREVAIL II, and will make ZMapp available to Ebola patients wishing to have access to this experimental treatment in participating countries.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top